Title: Eliglustat, an investigational oral therapy for Gaucher disease type 1: Phase 2 trial results after 4 years of treatment.
Journal: Blood cells, molecules & diseases 20141201
Title: Eliglustat: first global approval.
Journal: Drugs 20141001
Title: Property-based design of a glucosylceramide synthase inhibitor that reduces glucosylceramide in the brain.
Journal: Journal of lipid research 20120201
Title: Evaluation of quinazoline analogues as glucocerebrosidase inhibitors with chaperone activity.
Journal: Journal of medicinal chemistry 20110224
Title: Improvement in hematological, visceral, and skeletal manifestations of Gaucher disease type 1 with oral eliglustat tartrate (Genz-112638) treatment: 2-year results of a phase 2 study.
Journal: Blood 20101118
Title: Eliglustat tartrate, an orally active glucocerebroside synthase inhibitor for the potential treatment of Gaucher disease and other lysosomal storage diseases.
Journal: Current opinion in investigational drugs (London, England : 2000) 20101001
Title: A phase 2 study of eliglustat tartrate (Genz-112638), an oral substrate reduction therapy for Gaucher disease type 1.
Journal: Blood 20100812
Title: Improved management of lysosomal glucosylceramide levels in a mouse model of type 1 Gaucher disease using enzyme and substrate reduction therapy.
Journal: Journal of inherited metabolic disease 20100601
Title: Increased hepatic insulin action in diet-induced obese mice following inhibition of glucosylceramide synthase.
Journal: PloS one 20100101
Title: Substrate reduction augments the efficacy of enzyme therapy in a mouse model of Fabry disease.
Journal: PloS one 20100101
Title: A specific and potent inhibitor of glucosylceramide synthase for substrate inhibition therapy of Gaucher disease.
Journal: Molecular genetics and metabolism 20070701
Title: McEachern KA, et al. A specific and potent inhibitor of glucosylceramide synthase for substrate inhibition therapy ofGaucher disease. Mol Genet Metab. 2007 Jul;91(3):259-68.
